(616: Kb)

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC (616 KB)

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). : Patients in clinical trials were generally younger,

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can: : Investigating approaches where patients only take the

: Finding ways to help patients manage side effects so they can stay on the therapy longer.

The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on:

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .